Norbert Bräu

8.5k total citations · 1 hit paper
68 papers, 2.2k citations indexed

About

Norbert Bräu is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Norbert Bräu has authored 68 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hepatology, 41 papers in Epidemiology and 16 papers in Infectious Diseases. Recurrent topics in Norbert Bräu's work include Hepatitis C virus research (55 papers), Liver Disease Diagnosis and Treatment (32 papers) and Hepatitis B Virus Studies (17 papers). Norbert Bräu is often cited by papers focused on Hepatitis C virus research (55 papers), Liver Disease Diagnosis and Treatment (32 papers) and Hepatitis B Virus Studies (17 papers). Norbert Bräu collaborates with scholars based in United States, United Kingdom and Italy. Norbert Bräu's co-authors include Mark Sulkowski, M. Rodríguez‐Torres, Edmund J. Bini, Douglas T. Dieterich, Fiorenzo Paronetto, José F. Rodríguez‐Orengo, Carlos F. Ríos‐Bedoya, Stanislas Pol, Mirella Salvatore and Tarek Hassanein and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

Norbert Bräu

67 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

2017 271 citations Edward Gane, Eric Lawitz et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Norbert Bräu United States	24	1.9k	1.6k	617	147	103	68	2.2k
Wolf Peter Hofmann Germany	24	1.8k 1.0×	1.7k 1.1×	268 0.4×	29 0.2×	45 0.4×	72	2.3k
F. Fabrizi Italy	32	2.5k 1.3×	2.3k 1.4×	346 0.6×	58 0.4×	27 0.3×	109	3.0k
Patrick Ingiliz Germany	24	1.5k 0.8×	1.4k 0.9×	384 0.6×	103 0.7×	71 0.7×	98	1.8k
Joseph Sasadeusz Australia	16	1.2k 0.7×	1.2k 0.8×	545 0.9×	71 0.5×	105 1.0×	38	1.5k
JK Rockstroh Germany	19	417 0.2×	775 0.5×	782 1.3×	172 1.2×	420 4.1×	63	1.9k
Eugenia Vispo Spain	31	1.9k 1.0×	1.8k 1.1×	1.1k 1.8×	472 3.2×	489 4.7×	104	2.9k
E. Gower Switzerland	5	1.8k 0.9×	1.7k 1.0×	444 0.7×	71 0.5×	79 0.8×	5	2.0k
Juergen Rockstroh Germany	26	1.2k 0.6×	1.2k 0.7×	712 1.2×	221 1.5×	486 4.7×	47	2.0k
Gabriella Verucchi Italy	21	1.5k 0.8×	1.5k 0.9×	286 0.5×	152 1.0×	173 1.7×	86	2.0k
A Sánchez-Quijano Spain	18	984 0.5×	1.1k 0.7×	531 0.9×	184 1.3×	337 3.3×	52	1.7k

Countries citing papers authored by Norbert Bräu

Since Specialization

Citations

This map shows the geographic impact of Norbert Bräu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Bräu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Bräu more than expected).

Fields of papers citing papers by Norbert Bräu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Bräu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Bräu. The network helps show where Norbert Bräu may publish in the future.

Co-authorship network of co-authors of Norbert Bräu

This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Bräu. A scholar is included among the top collaborators of Norbert Bräu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Bräu. Norbert Bräu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fulgenzi, Claudia Angela Maria, Alessia Dalla Pria, Alberto Giovanni Leone, et al.. (2025). Hepatocellular carcinoma in people living with HIV. Journal of Hepatology. 83(4). 971–981.

Re, Vincent Lo, Craig Newcomb, Dena M. Carbonari, et al.. (2024). Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology and Drug Safety. 33(12). e70069–e70069. 1 indexed citations

Leuva, Harshraj, Mengxi Zhou, Norbert Bräu, et al.. (2022). Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans. Seminars in Oncology. 49(5). 363–370. 7 indexed citations

Newcomb, Craig, Dena M. Carbonari, Christopher T. Rentsch, et al.. (2021). Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal of Hepatology. 75(6). 1312–1322. 8 indexed citations

Taddei, Tamar H., Lesley S. Park, Dena M. Carbonari, et al.. (2019). Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 29(1). 71–78. 4 indexed citations

Kallan, Michael J., Dena M. Carbonari, Lesley S. Park, et al.. (2019). HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. JNCI Journal of the National Cancer Institute. 112(7). 747–755. 17 indexed citations

Fuchs, Michael, Alexander Monto, Norbert Bräu, et al.. (2019). Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders. Journal of Medical Virology. 92(12). 3459–3464. 1 indexed citations

Younossi, Zobair M., Maria Stepanova, Tarik Asselah, et al.. (2017). Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clinical Infectious Diseases. 66(11). 1742–1750. 18 indexed citations

Gane, Edward, Eric Lawitz, David Pugatch, et al.. (2017). Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. New England Journal of Medicine. 377(15). 1448–1455. 271 indexed citations breakdown →

10.

Bräu, Norbert. (2012). Evaluation of the Hepatitis C Virus-Infected Patient: The Initial Encounter. Clinical Infectious Diseases. 56(6). 853–860. 8 indexed citations

11.

Kikuchi, Luciana, Pablo Barreiro, Mark Nelson, et al.. (2010). 1065 IMPACT OF SCREENING FOR HEPATOCELLULAR CARCINOMA (HCC) IN HIV/HCV-COINFECTED PATIENTS ON STAGING, THERAPY AND SURVIVAL. Journal of Hepatology. 52. S412–S412. 1 indexed citations

12.

Poordad, Fred, Norbert Bräu, Eric Lawitz, et al.. (2008). Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin. 1 indexed citations

13.

Soriano, Vincent, Massimo Puoti, Mark Sulkowski, et al.. (2007). Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel. AIDS. 21(9). 1073–1089. 256 indexed citations

14.

Hu, Ke‐Qin, Sue Currie, Hui Shen, et al.. (2007). Clinical Implications of Hepatic Steatosis in Patients with Chronic Hepatitis C: A Multicenter Study of U.S. Veterans. Digestive Diseases and Sciences. 52(2). 570–578. 20 indexed citations

15.

Rosman, Alan S., et al.. (2006). Decline in haemoglobin A1c values in diabetic patients receiving interferon‐alpha and ribavirin for chronic hepatitis C*. Journal of Viral Hepatitis. 13(9). 613–617. 17 indexed citations

16.

Rodríguez‐Torres, M., et al.. (2006). Progression to Cirrhosis in Latinos With Chronic Hepatitis C: Differences in Puerto Ricans With and Without Human Immunodeficiency Virus Coinfection and Along Gender. Journal of Clinical Gastroenterology. 40(4). 358–366. 25 indexed citations

17.

Hornberger, John, Francesca J. Torriani, Douglas T. Dieterich, et al.. (2006). Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Journal of Clinical Virology. 36(4). 283–291. 20 indexed citations

18.

Cheung, Ramsey, Sue Currie, Hui Shen, et al.. (2005). Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility, Acceptance, and Outcomes. The American Journal of Gastroenterology. 100(10). 2186–2193. 60 indexed citations

19.

Bräu, Norbert, M. Rodríguez‐Torres, Maurizio Bonacini, et al.. (2004). Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin. Hepatology. 39(4). 989–998. 62 indexed citations

20.

Carey, William, et al.. (1997). Cutaneous Protothecosis in a Patient with AIDS and a Severe Functional Neutrophil Defect: Successful Therapy with Amphotericin B. Clinical Infectious Diseases. 25(5). 1265–1266. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact